AAPS PharmSci 360 delivers research spanning the pharmaceutical product lifecycle. Thousands of scientists and leaders, representing large and small pharma from across the globe converge at this science-first event to discuss cutting-edge approaches and technologies.
Sessions and posters highlight recent innovations that can benefit early-stage researchers. RX-360, AstraZeneca, Mayo Clinic, and Merck are just some of the many organizations represented at this year’s event.
Join your colleagues in New Orleans, October 25-28, at the Ernest N. Morial Convention Center.
Don’t Miss These Sessions!
Monday, October 26
Executive Track: What Actually Drives Development Speed? An Executive-Level Autopsy of Drug Development Delays
Speakers: Tanya Karakyriakou, Ph.D. Candidate, University College London; Leigh Verbois, Ph.D., CEO, Rx-360; and Teresa R. Henry, Ph.D., President, Blue Oaks Biotech
From Guidance to Practice: Designing Regulatory‑Ready Biodistribution & Persistence Strategies Under ICH S12
Speaker: Nagendra Chemuturi, Ph.D., Senior Director, Eli Lilly
Sandwich-Cultured Hepatocytes, Multicellular Hepatic Spheroids, and Liver-on-a-Chip Systems
Speaker: Kim L.R Brouwer, Pharm.D., Ph.D., Interim Dean William R. Kenan, Jr., Distinguished Professor, UNC Eshelman School of Pharmacy
New Approach Methodologies for Immunogenicity Risk Assessment of Biotherapeutics
Speaker: Benjamin Gabriel, Ph.D., Research Scientist, EpiVax
PD-L1 Exosomes Reprogram Resistance in Breast and Pancreatic Cancer
Speaker: Mandip Singh Sachdeva, Ph.D., FAAPS, Professor and Section Leader Pharmaceutics, Florida A & M University
Tuesday, October 27
Advancing NAMs with Quantitative Systems Toxicology and Microphysiological Systems
Speaker: Jeffrey Woodhead, Ph.D., Senior Principal Scientist, Simulations Plus
Nanomedicine in Translation: From Design to Therapeutic Outcome
Speaker: Annette Bak, Ph.D., M.B.A., FAAPS, Executive Director, AstraZeneca
Clinical Consequences of GLP-1-Induced Gastric Emptying Delay
Speaker: Jessica Atieh, M.D., Gastroenterology and Hepatology Fellow, Mayo Clinic
Scalable Human Organ-on-Chip Models for DILI and Oncology Applications
Speaker: Jing Bai, Ph.D., Manager of Advanced Research, Xellar Biosystems
A Human Lymphoid Chip Model for Vaccine Adjuvant Functional Evaluation
Speaker: Christine M. Hamadani, Ph.D., Postdoctoral Fellow/Associate Scientist, Merck
Wednesday, October 28
Cracking the Dose Code: Modeling Strategies for Dose Selection for Multispecific Biologics
Speaker: Ran Li, Ph.D., Senior Principal Scientist, Genentech
Hot Topic: Are Regulators on the Same Page for Pediatric Drug Data?
Speakers: Alysha Croker, Ph.D., Director, Strategic and Horizontal Policy, Health Canada; Smita Salunke, Ph.D., Senior Research Fellow/EuPFI CSO, University College London/European Paediatric Formulation Initiative; and John J. Alexander, M.D., M.P.H., Deputy Director, U.S. FDA
Potential Paradigm Shift in Basic Concepts of the Effects of Sunlight on Human Health and Its Regulatory Implications
Speaker: Win L. Chiou, Ph.D., Retired Professor, University of Illinois at Chicago
Recent Advances in Predicting Complex Food Effects Using PBPK Modelling
Speaker: Siri Kalyan Chirumamilla, M.S., Associate Principal Scientist, Certara
Special Tracks Address Research Integrity and NAMs
This year, the conference also launches two Innovator-Curated tracks. These tracks highlight novel science and pressing issues and have been developed entirely by leaders in their respective fields.
On October 26, Brian Nosek inaugurates the first Innovator-Curated track, emphasizing research integrity with talks from experts at Northwestern University, NIH, and the Coalition for Aligning Science. Then, on October 28, Dr. Thomas Hartung from Johns Hopkins University leads sessions addressing New Approach Methodologies, or NAMs, with insights from researchers at Tulane University, 28Bio, and VeriSim Life.
Plenaries Address Public Health and Healthcare Innovation
Julie Gerberding, M.D., M.P.H., President and CEO of President and CEO of the Foundation for the National Institutes of Health (FNIH), opens the event on Sunday, October 25, with her insights into public health. David Berry, M.D., Ph.D., Managing Partner at Averin Capital, closes out PharmSci 360 on Wednesday, October 28, with a look at how technology is transforming the pharmaceutical market.
NEW! USP Sessions in Exhibit Hall
AAPS and the United States Pharmacopeia (USP) are excited to announce an exciting new partnership at this year’s PharmSci 360. Inside the exhibit hall, USP scientists will host sessions offering insights on complex generics, excipient quality, inhalation standards, emerging standards, and novel excipients. All PharmSci 360 attendees have access to these sessions, held during exhibit hall hours.
Speaking of the exhibit hall, make sure you take some time to see new scientific solutions from both industry stalwarts and emerging companies such as 10x Genomics, Agilent Technologies, IQVIA, Pion, SCIEX, and Thermo Fisher Scientific.
Also in the exhibit hall, Careers 360 resources include sessions featuring recruiters, executives, coaches, and other experts who are helping today’s scientists grow their careers. Attend relaxed, interactive sessions on AI skill-building, credentialing, IP, and securing startup funding. Plus, practice interviewing and get your resume reviewed.
Join AAPS in New Orleans October 25-28 and let PharmSci 360 help you build your knowledge and your network.
Save My Seat!Sponsored content by AAPS
Filed Under: Sponsored Content
